Vir Biotechnology, Inc. (VIR)

NASDAQ • Healthcare

$10.57

+$0.14 (+1.3%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$10.36

Previous Close$10.57

Day Range$10.03 - $10.59

Avg. Volume (3M)1.9M

Market Cap$1.7B

52 Week Range

$4.82$12

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$238.9M100%

Gross Profitminus cost of goods$236.1M99%

Operating Incomeminus R&D and overhead$74.5M31%

Net Incomeminus taxes and the rest$80M34%

In plain terms: out of every $100 in revenue, Vir Biotechnology, Inc. keeps $34 as net profit.

Fundamentals & Financials

Revenue (TTM)

$303.2M

Net Income (TTM)

-$251.6M

EPS (TTM)

-$1.85

ROA (TTM)

-20.72%

Current Ratio

6.04

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-11.1%Q3 2025-$0.8

-67.1%Q4 2025-$1.17

+26.2%Q1 2026-$0.31

-8400.0%Q2 2026-$0.85

+41.3%Q3 2026$0.47

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +41.3%

Vir Biotechnology’s revenue fell year over year in the second fiscal quarter of 2026, which it reported on August 5, 2026, as the company continued to focus on its antibody and infectious-disease medicines portfolio led by Sotrovimab (Xevudy) alongside pipeline programs in hepatitis B, influenza A, and HIV. Operating cash flow was negative at roughly -$9.1 million, reflecting cash use during the period. For the next period, consensus calls for EPS of -$0.74 on revenue of $865,125.00.

Next report — what to expect

Vir Biotechnology, Inc. (VIR) is set to report earnings on November 4, 2026. Consensus calls for EPS of -$0.739 on revenue of $865,125.00. For trailing context, revenue grew +19582.5% year over year last quarter. VIR has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. develops antibody and infectious-disease medicines and is listed on the NASDAQ Global Select Market under the ticker VIR. The company operates in biotechnology within healthcare, with FY2025 revenue of $68.6 million, and its commercial identity centers on Sotrovimab, marketed as Xevudy for SARS-CoV-2 treatment and prevention.

Name

Vir Biotechnology, Inc.

CEO

Marianne De Backer

Website

www.vir.bio

Industry

Healthcare

Year Founded

2016

Employees

367

Today's Snapshot

AI-generated

VIR closed 1.3% higher at 10.57, outperforming a weaker sector. Earnings are due from VIR on 4 November.

Trading Volume

Above 10d avg 1.5M

1.6M

vs S&P 500 Today

Outperforming Market

+1.86%

Updated: October 23, 2026 at 20:22 UTC

Technical Indicators

2 Buy2 Neutral4 Sell

VIR shows a modestly negative technical profile driven by weakening momentum and muted trend strength. Price sits near short-term averages while medium-term SMAs remain slightly above today’s quote, and the MACD and momentum readings are negative, suggesting a short-term bias toward selling. ADX near the mid-teens indicates a lack of a strong directional trend, meanwhile ATR is elevated relative to price, pointing to larger-than-normal intraday moves and OBV is soft, so volume does not confirm strength. Technical takeaway: Sell.

All signals